phrykt

CareDx, Inc. (CDNA): who owns it and who trades it

As of Nov 16, 2026, CDNA insiders reported 41 open-market sales worth $19.7M and no purchases in the last 12 months, with 82% of the sale value made under pre-set 10b5-1 plans. The largest seller was John Walter Hanna JR (CEO), with $7.5M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling CareDx

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CDNA

228 funds and institutions reported CDNA shares worth $1.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.9.3%
State Street Corp4.8%
Vanguard Capital Management LLC4.3%
Deerfield Management Company, L.P.3.9%
ARK Investment Management LLC3.8%
Boston Partners3.8%
Bamco Inc3.8%
Gagnon Securities LLC3.4%
California State Teachers Retirement System3.0%
Chevy Chase Trust Holdings, LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.4.81M9.32%$137M+6%
State Street Corp2.47M4.78%$70.4M-11%
Vanguard Capital Management LLC2.20M4.25%$62.6M+2%
Deerfield Management Company, L.P.2.00M3.87%$56.9M-9%
ARK Investment Management LLC1.95M3.78%$55.7M-12%
Boston Partners1.94M3.75%$55.2M+3%
Bamco Inc1.94M3.75%$55.2M-42%
Gagnon Securities LLC1.77M3.43%$50.5M+1%
California State Teachers Retirement System1.55M3.01%$54.5M+3286%
Chevy Chase Trust Holdings, LLC1.44M2.78%$41M-4%
Geode Capital Management, LLC1.33M2.57%$37.9M+6%
Ophir Asset Management Pty Ltd1.26M2.45%$36M+28%
Renaissance Technologies LLC1.24M2.41%$35.4M+5%
Braidwell LP1.22M2.36%$34.8M-44%
First Eagle Investment Management, LLC1.20M2.32%$34.1M+108%
Sumitomo Mitsui Trust Group, Inc.1.19M2.31%$34M-19%
Blue Water Life Science Advisors, LP1.19M2.30%$33.9M+27%
Amova Asset Management Americas, Inc.1.19M2.30%$33.8M-19%
Dimensional Fund Advisors LP1.18M2.29%$33.7M-19%
D. E. Shaw & Co., Inc.1.14M2.20%$32.4M+30%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CDNA insiders reported $0 of open-market purchases and $19.7M of sales. 82% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$19.7M
41 trades, 8 people
Sales under a 10b5-1 plan
82%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$6.4M$6.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Michael GoldbergDirectorSale plan3,547$78.32$278KForm 4
Nov 12, 2026Michael GoldbergDirectorSale plan8,024$79.32$636KForm 4
Nov 12, 2026Michael GoldbergDirectorSale plan2,229$79.85$178KForm 4
Nov 12, 2026Keith KennedyCFOSale plan800$78.78$63KForm 4
Nov 12, 2026Keith KennedyCFOSale plan1,297$79.61$103KForm 4
Nov 10, 2026Jeffrey Adam NovackSecretary and General CoSale plan2,996$80.47$241KForm 4
Nov 10, 2026Jeffrey Adam NovackSecretary and General CoSale plan200$81.05$16.2KForm 4
Nov 10, 2026Jeffrey Adam NovackSecretary and General CoSale plan900$83.33$75KForm 4
Nov 5, 2026Keith KennedyCFOSale plan28,256$76.55$2.2MForm 4
Nov 5, 2026Keith KennedyCFOSale plan12,380$77.42$958KForm 4
Nov 5, 2026Keith KennedyCFOSale plan6,897$78.59$542KForm 4
Nov 5, 2026Keith KennedyCFOSale plan7,415$79.49$589KForm 4
Nov 5, 2026Keith KennedyCFOSale plan3,403$80.38$274KForm 4
Nov 5, 2026Keith KennedyCFOSale plan2,710$81.40$221KForm 4
Nov 5, 2026Keith KennedyCFOSale plan300$82.08$24.6KForm 4
Nov 5, 2026Keith KennedyCFOSale plan600$83.60$50.2KForm 4
Aug 5, 2026George BickerstaffDirectorSale20,000$46.29$926KForm 4
Aug 5, 2026Jeffrey Adam NovackSecretary and General CoSale plan2,188$46.15$101KForm 4
Aug 5, 2026Jeffrey Adam NovackSecretary and General CoSale plan500$46.75$23.4KForm 4
Aug 4, 2026Christine CournoyerDirectorSale plan16,000$46.94$751KForm 4
Aug 4, 2026Michael GoldbergDirectorSale44,700$47.06$2.1MForm 4
Jul 16, 2026John Walter Hanna JRCEOSale plan68,000$39.01$2.7MForm 4
Jul 16, 2026John Walter Hanna JRCEOSale plan50,000$36.11$1.8MForm 4
Jul 16, 2026Hannah ValantineDirectorSale plan100$36.55$3.7KForm 4
Jul 16, 2026Hannah ValantineDirectorSale plan28,679$36.14$1MForm 4
Jun 29, 2026John Walter Hanna JRCEOSale plan39,900$29.24$1.2MForm 4
Jun 26, 2026John Walter Hanna JRCEOSale plan100$29.00$2.9KForm 4
Jun 15, 2026John Walter Hanna JRCEOSale plan17,683$24.03$425KForm 4
Jun 15, 2026Hannah ValantineDirectorSale plan12,103$23.11$280KForm 4
Jun 11, 2026John Walter Hanna JRCEOSale plan21,998$24.02$528KForm 4
Jun 4, 2026John Walter Hanna JRCEOSale plan4,835$24.00$116KForm 4
May 15, 2026Arthur A TorresDirectorSale6,484$19.89$129KForm 4
May 14, 2026Arthur A TorresDirectorSale4,086$20.97$85.7KForm 4
May 5, 2026Jeffrey Adam NovackSecretary and General CoSale2,688$20.68$55.6KForm 4
Apr 16, 2026John Walter Hanna JRCEOSale plan10,282$21.12$217KForm 4
Feb 3, 2026Jeffrey Adam NovackSecretary and General CoSale4,441$20.56$91.3KForm 4
Jan 22, 2026John Walter Hanna JRCEOSale plan19,280$21.16$408KForm 4
Jan 21, 2026John Walter Hanna JRCEOSale plan200$21.00$4.2KForm 4
Jan 15, 2026John Walter Hanna JRCEOSale plan10,156$21.05$214KForm 4
Dec 4, 2025Jeffrey Adam NovackSecretary and General CoSale286$19.75$5.6KForm 4
Dec 4, 2025Jeffrey Adam NovackSecretary and General CoSale7,007$19.15$134KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John Walter Hanna JRPresident and CEO, Director–$7.5MJul 16, 2026
Keith KennedyCFO & COO–$5MNov 12, 2026
Michael GoldbergDirector–$3.2MNov 12, 2026
Hannah ValantineDirector–$1.3MJul 16, 2026
George BickerstaffDirector–$926KAug 5, 2026
Christine CournoyerDirector–$751KAug 4, 2026
Jeffrey Adam NovackSecretary and General Counsel–$743KNov 10, 2026
Arthur A TorresDirector–$215KMay 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CDNA short interest

High short interest. 13.7% of CDNA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.19M CDNA shares were sold short, 13.7% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 5.3 trading days (days to cover).

Shares short, % of all shares

13.7%May 15Oct 3017.1%

Days to cover

5.3May 15Oct 3012.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.19M13.68%+7%1.36M5.3
Oct 15, 20266.72M12.98%+2%1.49M4.5
Sep 30, 20266.59M12.73%+5%1.44M4.6
Sep 15, 20266.30M12.17%+8%1.00M6.3
Aug 31, 20265.83M11.27%+1%1.21M4.8
Aug 14, 20265.79M11.19%-6%1.15M5.0
Jul 31, 20266.14M11.86%-1%1.44M4.2
Jul 15, 20266.19M11.98%-26%797,4567.8
Jun 30, 20268.34M16.14%-1%1.15M7.3
Jun 15, 20268.43M16.33%+32%784,95410.8
May 29, 20266.37M12.33%-2%703,3119.1
May 15, 20266.51M12.60%-6%574,54011.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CareDx company events

CareDx filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Sep 16, 2026DealAmended an earlier report. CareDx, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission reporting the completion of its acquisition of Naveris, Inc., a Delaware corporation. Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. Jul 7, 2026DealCareDx, Inc. completed the previously announced sale of the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software to Eurobio Scientific S.A., pursuant to and subject to the terms… Filing
  5. Jun 15, 2026LeadershipCareDx, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  6. Apr 28, 2026AgreementCareDx, Inc. entered into an Agreement and Plan of Merger with Naveris, Inc., a Delaware corporation, Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, and Shareholder Representative Services LLC, solely in its capacity as the representative of the… Filing
  7. Apr 23, 2026LeadershipAmended an earlier report. As previously disclosed in the Original Report, on February 24, 2026, the Company appointed Keith Kennedy, the Company’s previous Chief Operating Officer, as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026. Filing
  8. Apr 16, 2026AgreementCareDx, Inc. entered into a Purchase Agreement with Eurobio Scientific S.A., pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to… Filing
  9. Feb 25, 2026LeadershipAmended an earlier report. The Board of Directors of the Company has appointed Keith Kennedy as the Company’s Chief Financial Officer and Chief Operating Officer, effective as of February 26, 2026. Filing
  10. Feb 24, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 18, 2025AnnouncementAn unopposed motion for the preliminary approval of settlement was filed after CareDx, Inc. reached an agreement in principle for a proposed settlement of a shareholder derivative litigation, captioned Edelman, et al., v. Filing
  13. Dec 15, 2025RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CareDx financials

Famous investors that hold CDNA

5 of the 50 well-known investors we track reported holding CDNA in their latest 13F filing. The largest position is Cathie Wood's, worth $105M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 20261.61M$105M0.6%-18%
Jim Simons · Renaissance TechnologiesQ3 20261.26M$81.6M0.1%+1%
Ken Griffin · Citadel AdvisorsQ3 20261.14M$73.8M0.0%+962%
Israel Englander · Millennium ManagementQ3 2026258,531$16.8M0.0%+250%
Steve Cohen · Point72 Asset ManagementQ3 2026109,858$7.1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CDNA in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G5.1%
Nov 10, 2026STATE STREET CORPORATION13G5.1%

Questions about CareDx, Inc. (CDNA) stock

Who owns the most CDNA stock?

The largest reported owner of CareDx, Inc. (CDNA) is BlackRock, Inc., with 9.3% of the company. In total, 228 funds and institutions reported holding CDNA at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CDNA insiders buying or selling?

In the last 12 months, CDNA insiders reported no open-market purchases and 41 sales worth $19.7M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in CDNA?

As of Oct 30, 2026, 7.19M CDNA shares were sold short, 13.7% of the shares outstanding, up 7.0% from the report before. At the average daily volume of 1.36M shares, buying them all back would take about 5.3 trading days (days to cover). See the history.

Which famous investors hold CDNA?

5 of the 50 well-known investors we track reported CDNA in their latest 13F filing, including Cathie Wood, Jim Simons, Ken Griffin. The largest position is worth $105M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.